OBJECTIVES: This study aims to compare the costs of available recombinant VIII factors available in Mexico for prophylactic treatment of severe Haemophilia-A in pediatric patients, from the public payer perspective. perspective.

METHODS: A cost-minimization model (fo anual costs) was developed to estimate the treatment cost associated with lonoctocog-alfa, compared to turoctocog-alfa, moroctocog-alfa, octocog-alfa and simoctocog-alfa in pediatric patients with severe Haemophilia-A. Annual prophylactic dosing were obtained from clinical trials of each drug, respectively. This Analysis is based on a matching-adjusted indirect comparison that demonstrated there was no statistically significant difference in the anual expected bleeding rate among the included treatment regimens, the included costs are only the factor consumption in prophylaxis and are expressed in 2022 USD. The outcome measured is the total costs (direct medical costs) for every treatment alternative. A probabilistic sensitivity analysis (first order Monte Carlo Simulation, 1,000 interactions) was developed to assess the robustness of the case base results.

RESULTS: Among all available rFVIII factors in Mexico, lonoctocog-alfa was found to be associated lower costs of treatment $23,302 vs $65,022 for turoctocog-alfa, and $86,370.00 associated to moroctocog-alfa, over a lifetime horizon. Compared to other rFVIII simoctocog-alfa and octocog-alfa, lonoctocog-alafa results in cost savings of $45,142 per patient, which represents a 66% of saving. The results of the probabilistic sensitivity analysis showed to be consistent to the base case analysis (1,000 Monte Carlo simulations per arm).

CONCLUSIONS: For the treatment of patients with severe Haemophilia-A in Mexico, lonoctocog-alfa was a cost-saving option compared to existing rFVII in Mexico from the public payer perspective.